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Implications	 for	
Nursing	Care
Japanese	Octopus	Traps	&	Broken	Hearts:	Takotsubo	Cardiomyopathy	
Chase	Smith	BSN,	RN,	CCRN
Introduction References
-Takotsubo	cardiomyopathy	(TTC)	is	a	non-
ischemic	cardiomyopathy	in	which	 there	 is	a	
“transient	 left	ventricular	systolic	 dysfunction,	
sparing	 the	basal	 segments	of	the	 left	
ventricle”	which	 results	 in	an	apical	ballooning	
appearance	of	the	 left	ventricle	(LV)	(Lesser,	
Maron &	Sharkey,	2011).	
-The	name	originates	 from	the	apical	
ballooning	 shape,	 found	via	left	
ventriculography	or	echocardiogram,	 that	is	
similar	 to	a	Japanese	octopus	 trap	called	
“takotsubo”	(Reeder	&	Prasad,	 2015).	Other	
common	names	include	apical	ballooning	
syndrome,	 stress-induced	 cardiomyopathy	or	
broken	heart	syndrome	 (Reeder	&	Prasad,	
2015).	
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-While	 TTC	remains	a	relatively	
benign	condition	with	a	good	prognosis	 for	
complete	recovery,	 the	three-fold	 increase	
in	 recognized	cases	between	2007-2012	
demands	awareness	of	 the	condition	
(Minhas,	 Hughey &	Kolias,	 2015).	
-While	 most	cases	carry	low	
mortality	 rates,	 cardiogenic	shock	and	
cardiac	arrest	can	accompany	TTC	in	
severe	cases	contributing	 to	 increased	
mortality	 rates	 in	certain	cases	(Liang,	Cha,	
Oh	&	Prasad,	2013).	
-This	varied	presentation	of	 the	
disease	 can	make	the	diagnosis	 of	TTC	
difficult,	 with	a	diagnosis	 typically	made	
after	invasive	cardiovascular	 testing	 is	
complete	(Reeder	&	Prasad,	2015).	
-While	 both	increased	 levels	of	
circulating	catecholamines	and	coronary	
artery	vasospasm/dysfunction	 are	strong	
theories	 for	the	cause	of	TTC	a	definitive	
cause	is	yet	 to	be	 identified	 (Lesser,	Maron
&	Sharkey,	2011).		
-Interestingly	TTC	is	usually	 triggered	
by	a	physical	or	emotional	 stressor	 in	 the	
patient’s	 life	and	occurs	predominantly	 in	
females,	 though	mortality	 rates	in	males	
can	be	up	 to	 four	times	higher	 than	
females	 (Khera,	 Light-McGroary,	Kahr,	
Horwitz	&	Girotra,	2016).	
-Treatment	primarily	mirrors	 that	of	
congestive	heart	failure	and	can	usually	be	
discontinued	 after	return	of	LV	 function	
(typically	within	 weeks	of	condition	onset)	
with	 recurrence	rates	of	the	condition	
around	5%	 (Lesser,	Maron&	Sharkey,	
2011).	
Figure	2 Harvard	University,	 2016
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Monitoring
-In	the	acute	care	setting,	 care	for	
patients	with	TTC	should	 include	close	
hemodynamic	and	electrocardiographic	
monitoring	as	 shock	and	malignant	
arrhythmias	are	known	to	occur,	and	are	
the	biggest	contributors	of	death	 from	TTC	
(Liang,	Cha,	Oh,	Prasad,	2013).	
Treatment
-Administration	 of	appropriate	
medications	ACEIs/ARBs,	 diuretics,	 beta	
blockers	and	possibly	 anticoagulation	
should	 be	provided	 to	promote	recovery	of	
LV	function	 (Andrade	&	Stainback,	2014).	
Trigger	Identification	&	
Avoidance
-A	 thorough	history	and	assessment	
may	provide	clues	 to	a	possible	 emotional	
or	physical	 trigger,	 if	one	exists	 (Inggs&	
Christensen,	 2015).	
-If	a	trigger	 is	 identified	education	
specific	 to	avoiding	 that	trigger	may	prove	
beneficial,	 as	1	 in	20	patients	can	suffer	a	
recurrence	of	the	disease	 (Lesser,	 Maron&	
Sharkey,	2011).	
Education
-Medication	and	disease	 education	
should	 be	provided	 to	 improve	compliance	
with	 treatment	to	help	 increase	 the	
chances	of	a	 full	 recovery	(Lesser,	Maron&	
Sharkey,	2011).	
-Education	regarding	anginal	 symptoms	
(Pore	&	Burley,	 2012)	should	 be	provided	
as	TTC	patients	could	experience	occlusive	
coronary	artery	disease	 in	 the	future	and	
they	should	 not	omit	seeking	 treatment	
because	they	have	had	or	are	recovering	
from	TTC.	
Proposed	 Underlying	
Pathophysiology
Increased	 Catecholamine	Levels
-The	first	 includes	 increased	 levels	of	
circulating	catecholamines	that	cause	
decreased	contractility	and	myocardial	
stunning	 (Pelliccia,	Greco,	Vitale,	 Rosano,	
Gaudio &	Kaski,	 2014).	It	is	believed	 that	
increased	catecholamines	damage	myocytes	
through	cyclic	adenosine	monophosphate	
(CAMP)	calcium	overload	and	increased	 levels	
of	free	 radiacls (Pelliccia,	Greco,	Vitale,	 Rosano,	
Gaudio &	Kaski,	 2014).
Coronary	Artery	Vasospasm	&	
Microvascular	 Dysfunction.												
-Another	common	hypothesis	 includes	
coronary	artery	vasospasm	and	coronary	artery	
microvascular	dysfunction	producing	 the	
transient	 left	ventricular	dysfunction	 found	in	
TTC	(Liang,	Cha,	Oh,	Prasad,	2013).	Arterial	
vasospasm	of	large	epicardial coronary	arteries	
and	microvascular	coronary	arteries	are	known	
to	have	the	potential	 to	cause	significant	
cardiac	disease	as	Prinzmetal’s angina
-Ultimately,	 regardless	 of	the	cause	treatment	must	be	provided	 to	avoid	
worsening	 of	LV	dysfunction,	 which	can	lead	to	ventricular	arrhythmias,	
permanent	ventricular	dysfunction	and/or	death.	Since	TTC	 initially	 presents	 in	
a	similar	 fashion	as	ACS,	 the	 treatment	of	the	patient	 should	 follow	 ACS	
guidelines	 initially	 until	 ACS	can	be	 ruled	out	and	TTC	made.	Frequently	 this	
involves	coronary	angiography,	 either	emergently	or	urgently,	 to	rule	out	
obstructive	coronary	artery	disease	 (Scantlebury &	Prasad,	 2014).	
Treatment
-Fortunately,	 conservative	therapy	 that	mimics	general	heart	 failure	
treatment	is	 successful	at	 resolving	most	cases	of	TTC	(Reeder	&	Prasad,	
2015).	Due	to	 the	lack	of	a	unified,	accepted	theory	for	 the	underlying	
pathophysiology	 of	TTC	a	 large	amount	of	treatment	is	 supportive	 in	nature,	
attempts	 to	avoid	 the	provocation	of	proposed	 causes	and	mirrors	 treatment	
for	heart	failure.	No	evidence	based	 treatment	currently	exists	 for	TTC	
(Reeder	&	Prasad,	 2015).	
-If	profound	shock	is	present	 treatment	may	include	mechanical	therapy,	
such	as	insertion	 of	an	intra-aortic	balloon	pump	 (IABP),	or	inotropic	 therapy	if	
necessary.	
-Ideally	inotropes	 should	 be	avoided	given	a	 surge	in	catecholamines	 is	
theorized	 to	be	one	of	 the	causative	factors	of	the	disease	 (Reeder	&	Prasad,	
2015).	
-Initially	beta	blockers,	 angiotension-convering enzyme	 inhibitors	 (ACEIs)	or	
angiotensin	 receptor	blockers	 (ARBs)	and	diuretics	 should	 be	used	 to	 treat	LV	
dysfunction	 (Kono &	Sabbah,	2014).	
-Anticoagulation	 should	be	used	 in	 severe	cases	of	LV	failure	 to	prevent	
thromboembolism	 (Reeder	&	Prasad,	2015)	which	could	cause	stroke	or	other	
end-organ	 ischemia.	
-Beta	blockers	have	been	used	 in	 some	patients	 after	recovery	of	LV	
function	due	to	 their	 catecholamine-inhibiting	 nature	however	 there	 is	no	
conclusive	standard	of	care	on	TTC	treatment	(Reeder	&	Prasad,	 2015).
-ACEIs/ARBs,	 diuretics	and	anticoagulation	should	 be	discontinued	 after	LV	
recovery	unless	 there	are	other	concomitant	diseases	 requiring	 their	use	
(Andrade	&	Stainback,	2014).	
Summary	of	Treatment
-Conservative	 therapy	that	mimics	general	heart	failure	 treatment
-Profound	shock	treatment	à IABP	&	 inotropic	 therapy	 if	necessary
-Avoidance	of	inotropes	 if	possible	 due	to	 their	possible	 role	 in	 the	disease
-Beta	blockers,	 ACEIs	or	ARBs	 and	diuretics	 for	LV	dysfunction
-Individualized	 discontinuation	 of	treatment	with	 recovery
-Table	1	content	taken	from	Scantlebury &	Prasad,	 2015
Signs	&	Symptoms
-TTC	frequently	mimics	a	ST-segment	elevated	myocardial	 infarction	(STEMI)	and/or	acute	coronary	
syndrome	 (ACS)	with	 acute	chest	pain,	dyspnea,	 syncope	and/or	 signs	of	heart	failure	 (Reeder	&	
Prasad,	2015)	with	severe	cases	presenting	 in	cardiogenic	 shock	(Liang,	Cha,	 Oh	&	Prasad,	2013).	
Treatment	for	TTC	is	generally	 supportive,	 with	 the	disease	being	predominantly	benign	 in	nature,	
though	some	individuals	 presenting	with	severe	symptoms	experience	high	mortality	 rates	(Liang,	
Cha,	Oh	&	Prasad,	 2013).	
-The	onset	of	 the	disease	 is	often	caused	by	an	intense	 emotional	 stressor	 such	as	 the	loss	 of	a	
loved	one,	an	interpersonal	 conflict	or	a	catastrophic	medical	diagnosis	 (Sharkey,	Pink,	 Lesser,	
Garberich,	Maron &	Maron,	2015)	but	can	have	physical	 triggers	 such	as	infection,	 surgery	or	
respiratory	 failure,	 while	 some	have	no	obvious	 inciting	events	or	diseases.	 	Women,	 particularly	post-
menopausal	women,	are	at	a	much	greater	risk	 than	males	 for	developing	TTC	with	approximately	
90%	of	cases	occurring	in	 females	(Minhas,	 Hughey &	Kolias,	 2015).
-The	similarity	 in	 symptoms	is	 both	a	blessing	 and	a	curse	as	patients	 who	experience	the	
aforementioned	symptoms	 typically	seek	medical	attention	 relatively	quickly	as	 they	often	associate	
the	symptoms	with	a	heart	attack.	These	same	symptoms	can	easily	be	interpreted	 as	ACS	or	a	STEMI	
by	healthcare	providers,	 as	there	 is	no	unique	sign	or	 symptom	to	distinguish	 between	 the	two	
differential	 diagnoses,	 so	 individuals	 presenting	with	 similar	 symptoms	are	often	 treated	alike	until	
proven	otherwise	 (Scantlebury &	Prasad,	2014).	
Figure	1	Pelliccia,	Greco,	Vitale,	 Rosano,	Gaudio,	 &	Kaski,	 2014
Diagnostic	Tests	&	Features
-Typical	cardiac	diagnostic	 tests	 for	ACS,	STEMI	and	TTC	frequently	 share	similar	 results,	 including	
ST-segment	changes	on	EKG,	elevated	cardiac	biomarkers	and	wall	 motion	abnormalities	 on	
echocardiogram.	
-Emergent	or	urgent	coronary	angiography	 is	 frequently	 required	 to	exclude	the	diagnosis	 of	ACS	or	
STEMI	as	delays	 in	 treatment	for	 these	diagnoses	can	lead	 to	great	 increases	 in	morbidity	and	
mortality	 (Hafiz,	Naidu,	DeLeon,	Ismal,	Alkhatib,	 Lorenz,	E’Elia,	 Rosenthal	 &	Marzo,	 2013).	
-A	diagnostic	 feature	of	TTC	found	on	coronary	angiography	and	echocardiography	is	wall	motion	
abnormalities	 of	the	LV	mid-segments	with	or	without	apical	 involvement	that	extend	beyond	a	single	
coronary	artery	distribution	 (Scantlebury &	Prasad,	2014).
Mayo	Clinic	 Criteria	 for	Takotsubo	Cardiomyopathy	
1.	Transient	hypokinesis,	 akinesis,	 or	dyskinesis of	 the	left	ventricular	mid-segments	with	or	without	 apical	involvement;	
the	 regional	wall	motion	abnormalities	 extend	beyond	a	single	epicardial vascular	distribution;	 a	stressful	 trigger	 is	
often,	but	not	always	present.	
2.	Absence	of	obstructive	coronary	disease	 or	angiographic	evidence	of	acute	plaque	 rupture.	
3.	New	electrocardiographic	abnormalities	 (either	ST-segment	elevation	and/or	T-wave	inversion)	 or	modest	elevation	
in	cardiac	troponin.	
4.	Absence	of	pheochromocytoma	and	myocarditis	
Significance	of	Pathophysiology
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